Search

Your search keyword '"Di Bona, E."' showing total 6 results
Start Over Author "Di Bona, E." Publisher nature publishing group
6 results on '"Di Bona, E."'

1. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

Author

Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, and Lo-Coco F.

Published
2020

2. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

Author

Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz M, and European LeukemiaNet

Abstract

In 2008, a European registry of relapsed acute promyelocytic leukemia was established by the European LeukemiaNet. Outcome data were available for 155 patients treated with arsenic trioxide in first relapse. In hematological relapse (n = 104), 91% of the patients entered complete hematological remission (CR), 7% had induction death and 2% resistance, 27% developed differentiation syndrome and 39% leukocytosis, whereas no death or side effects occurred in patients treated in molecular relapse (n = 40). The rate of molecular (m) CR was 74% in hematological and 62% in molecular relapse (P = 0.3). All patients with extramedullary relapse (n = 11) entered clinical and mCR. After 3.2 years median follow-up, the 3-year overall survival (OS) and cumulative incidence of second relapse were 68% and 41% in hematological relapse, 66% and 48% in molecular relapse and 90 and 11% in extramedullary relapse, respectively. After allogeneic or autologous transplantation in second CR (n = 93), the 3-year OS was 80% compared with 59% without transplantation (n = 55) (P = 0.03). Multivariable analysis demonstrated the favorable prognostic impact of first remission duration >= 1.5 years, achievement of mCR and allogeneic or autologous transplantation on OS of patients alive after induction (P = 0.03, P = 0.01, P = 0.01) and on leukemia-free survival (P = 0.006, P < 0.0001, P = 0.003), respectively.

Published
2015

3. PML-RAR alpha kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy

Author

Cicconi, L, Divona, M, Ciardi, C, Ottone, T, Ferrantini, A, Lavorgna, S, Alfonso, V, Paoloni, F, Piciocchi, A, Avvisati, G, Ferrara, F, Di Bona, E, Albano, F, Breccia, M, Cerqui, E, Sborgia, M, Kropp, Mg, Santoro, A, Levis, A, Sica, Simona, Amadori, S, Voso, Mt, Mandelli, F, Lo-Coco, F, Sica, S (ORCID:0000-0003-2426-3465), Cicconi, L, Divona, M, Ciardi, C, Ottone, T, Ferrantini, A, Lavorgna, S, Alfonso, V, Paoloni, F, Piciocchi, A, Avvisati, G, Ferrara, F, Di Bona, E, Albano, F, Breccia, M, Cerqui, E, Sborgia, M, Kropp, Mg, Santoro, A, Levis, A, Sica, Simona, Amadori, S, Voso, Mt, Mandelli, F, Lo-Coco, F, and Sica, S (ORCID:0000-0003-2426-3465)

Abstract

The APL0406 study showed that arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are not inferior to standard ATRA and chemotherapy (CHT) in newly diagnosed, low-intermediaterisk acute promyelocytic leukaemia (APL). We analysed the kinetics of promyelocytic leukaemia-retinoic acid receptor-alpha (PML-RAR alpha) transcripts by real-time quantitative PCR (RQ-PCR) in bone marrow samples from 184 patients and assessed the prognostic impact of fms-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) in 159 patients enrolled in this trial in Italy. After induction therapy, the reduction of PML-RARa transcripts was significantly greater in patients receiving ATRA-CHT as compared with those treated with ATRA-ATO (3.4 vs 2.9 logs; P = 0.0182). Conversely, at the end of consolidation, a greater log reduction of PML-RAR alpha transcripts was detected in the ATRA-ATO as compared with the ATRA-CHT group (6.3 vs 5.3 logs; P = 0.0024). FLT3-ITD mutations had no significant impact on either event-free survival (EFS) or cumulative incidence of relapse in patients receiving ATRA-ATO, whereas a trend for inferior EFS was observed in FLT3-ITD-positive patients receiving ATRA-CHT. Our study shows at the molecular level that ATRA-ATO exerts at least equal and probably superior antileukaemic efficacy compared with ATRA-CHT in low-intermediaterisk APL. The data also suggest that ATRA-ATO may abrogate the negative prognostic impact of FLT3-ITD.

Published
2016

4. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation

Author

Tedeschi, A, Cairoli, R, Marenco, P, Nosari, A, Tresoldi, E, Di Bona, E, Montillo, M, Morra, E, Tedeschi A, Cairoli R, Marenco P, Nosari A, Tresoldi E, Di Bona E, Montillo M, Morra E, Tedeschi, A, Cairoli, R, Marenco, P, Nosari, A, Tresoldi, E, Di Bona, E, Montillo, M, Morra, E, Tedeschi A, Cairoli R, Marenco P, Nosari A, Tresoldi E, Di Bona E, Montillo M, and Morra E

Published
2002

5. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation

Author

Marco Montillo, E. Morra, Paola Marenco, Annamaria Nosari, Alessandra Tedeschi, Elisabetta Tresoldi, Roberto Cairoli, E. Di Bona, Tedeschi, A, Cairoli, R, Marenco, P, Nosari, A, Tresoldi, E, Di Bona, E, Montillo, M, and Morra, E

Subjects
Acute promyelocytic leukemia, Hybrid gene, Cancer Research, medicine.medical_treatment, dexamethasone, Biology, mercaptopurine, methotrexate, mitoxantrone, chemistry.chemical_compound, Chimera (genetics), cytarabine, medicine, retinoic acid, Arsenic trioxide, Autogenous bone, Chemotherapy, Marrow transplantation, fungi, Hematology, medicine.disease, cyclosporin, arsenic trioxide, medicine.anatomical_structure, Oncology, chemistry, Cancer research, cyclophosphamide, Bone marrow
Abstract

Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation

Published
2002

6. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.

Author

Bassan R, Rohatiner AZ, Lerede T, Di Bona E, Rambaldi A, Pogliani E, Rossi G, Fabris P, Morandi S, Casula P, Carter M, Lambertenghi-Deliliers G, Lister TA, and Barbui T

Subjects
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Asparaginase administration & dosage, Bone Marrow Transplantation, Carmustine administration & dosage, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cytarabine administration & dosage, Dexamethasone administration & dosage, Disease-Free Survival, Etoposide administration & dosage, Female, Fusion Proteins, bcr-abl genetics, Gene Expression Regulation, Leukemic, Humans, Life Tables, Male, Melphalan administration & dosage, Mercaptopurine administration & dosage, Middle Aged, Neoplasm Proteins genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Prednisone administration & dosage, Remission Induction, Retrospective Studies, Teniposide administration & dosage, Transplantation, Autologous, Treatment Outcome, Vincristine administration & dosage, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin administration & dosage, Fusion Proteins, bcr-abl biosynthesis, Idarubicin administration & dosage, Neoplasm Proteins biosynthesis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Introduction: The use of anthracycline antibiotics in adult acute lymphoblastic leukemia (ALL) has resulted in an improved outcome to remission induction therapy. However,the exact role of these drugs in consolidation therapy is less clear, especially in specific ALL subsets., Materials and Methods: A retrospective analysis was conducted on the outcome of 308 patients (median age 35 years, range 13-75) with the most frequent subtype, early-B ALL, treated between 1974 and 1998 on eight consecutive protocols. Anthracycline-related effects were assessed by evaluating the impact of planned anthracycline dose-intensity (A-DI) on long-term outcome. A-DI (in mg/m(2)/week) during the first twelve weeks of consolidation therapy was classified as either "high" (doxorubicin>20, idarubicin>7) or "low"., Results: Complete remission was achieved in 78% of cases. With a median follow-up of 6.5 years, on multivariate analysis, disease-free survival (DFS) correlated only with expression of the Philadelphia (Ph) chromosome and/or associated BCR-ABL rearrangements (Ph/BCR(+)) (P=0.0001) and planned A-DI (P<0.0001). On this basis, four major prognostic groups with significantly different DFS could be identified: (1) Ph/BCR(-), "high" A-DI (n=102), median 3.5 years and 41% at five years, respectively; (2) Ph/BCR(-), "low" A-DI (n=64), 1.3 years and 16%; (3) Ph/BCR(+), "high" A-DI (n=35), 1.7 years and 20%; (4) Ph/BCR(+), "low" A-DI (n=39), 0.75 years and 0%. When analyzed separately for Ph/BCR(-) (n=166) and Ph/BCR(+) (n=74) patients, the A-DI effect on DFS was preserved in the former (P=0.018) whereas, in Ph/BCR(+) patients, only age <50 years (P=0.004) and blast count <25 x 10(9)/l (P=0.02) correlated with better DFS. However, Ph/BCR(+) patients with the best prognostic profile (age <50 years and blast count <25 x 10(9)/l; n=21) who were treated on "high" A-DI regimens experienced a median DFS of 2.2 years with DFS 21% at five years, compared to 0.67-1 years and 0-10% in other cases (n=53, P<0.01)., Conclusion: A "high" A-DI may act as a positive treatment-related prognostic factor in early B-lineage ALL. Although mainly restricted to patients with Ph/BCR(-) ALL, A-DI could also influence the outcome in Ph/BCR(+) patients with other favorable prognostic factors.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results